Major Depressive Episode Clinical Trial
— TOUCH-SOfficial title:
Affective Touch, Hedonia and Suicidal Behavior
Several elements suggest that suicidal vulnerability may be associated with an alteration in the perception of affective touch. On the one hand, anhedonia, characterized by a decrease in the pleasure felt, is strongly associated with suicidal ideation, independently of depression. However, the ability to feel pleasure is essential in the perception of affective touch. On the other hand, suicidal behaviors are associated with interpersonal difficulties, of which communication is an integral part, and communication is partly through touch. The investigators therefore wish to explore the perception of affective touch in suicidal behavior by using an affective tactile stimulation in 72 subjects with and without a history of suicide attempts (SA).
Status | Recruiting |
Enrollment | 72 |
Est. completion date | July 2023 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Being a woman - Aged between 18 and 65 - Past major depressive episode according to the DSM-5 criteria - Currently euthymic (Montgomery-Asberg Depression rating Scale (MADRS) < 12 and Young Mania Rating Scale (YMRS) < 6) - Minimal psychotropic medication (as determined by the clinician) - Able to understand experimental procedures - Able to speak, read and understand French - Having given written informed consent - For suicide attempters only: Lifetime history of suicide attempt - For affective controls only: No lifetime history of suicide attempt Exclusion Criteria: - Lifetime diagnosis of schizoaffective disorder, schizophrenia or autism spectrum disorder - Severe alcohol or substance use disorder in the past 6 months - Current anorexia nervosa - Diagnosis of mental retardation or severe medical comorbidity that is unstable or could interfere with measures (HIV, diabetes, cancer, chronic inflammatory disease, neurological disorder, sensory or cognitive disability) - Injury, scar, irritation/dermatological lesion or tattoo on the left forearm - Pregnancy or breastfeeding - Being in exclusion period for another study - Not being affiliated to the French National Social Security System - Being deprived of freedom (by judicial or administrative decision) - Being protected by law (guardianship or curatorship) - Having reached 4500€ annual compensation for participating to clinical trials |
Country | Name | City | State |
---|---|---|---|
France | Montpellier University Hospital, France (CHU) | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pleasantness of the touch | Perceived pleasantness of the tactile stimulation, assessed with a numeric scale ranging from -5 (very unpleasant) to +5 (very pleasant) | at inclusion | |
Secondary | Intensity of the touch | Perceived intensity of the tactile stimulation, assessed with a 10 points Likert scale (low intensity to high intensity). | at inclusion | |
Secondary | Decision-making performance (Iowa Gambling Test) | Decision-making performance using the IG index from the Iowa Gambling Test (difference between the number of safe and risky choices) | at inclusion | |
Secondary | Decision-making performance (Ultimatum Game) | Decision-making performance using the UG index from the Ultimatum Game (difference between the number of rejections of unfair and fair offers) | at inclusion | |
Secondary | ß-endorphin levels | Plasmatic levels of ß-endorphin | at inclusion | |
Secondary | Variation in the expression of opioidergic genes | Variation in mRNA levels of 6 genes coding for opioidergic receptors and peptides (OPRM1 (µ), OPRK1 (?), OPRD1 (d) and pro-opio-melanocortin, pro-enkephalin, pro-dynomorphin), before and after tactile stimulation | at inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Completed |
NCT01944293 -
Ketamine for Suicidality in Bipolar Depression
|
Phase 1/Phase 2 | |
Recruiting |
NCT01441505 -
A Study of Ketamine as an Antidepressant
|
Phase 2 | |
Active, not recruiting |
NCT03487926 -
Microglial Activation in Inflammatory Bowel Disease
|
||
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05028738 -
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
|
N/A | |
Recruiting |
NCT03646058 -
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
|
Phase 3 | |
Not yet recruiting |
NCT06117397 -
A Text Messaging Intervention to Reduce Perinatal Depression Risk
|
N/A | |
Completed |
NCT03735576 -
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
|
N/A | |
Recruiting |
NCT04999553 -
Left vs. Right Non-Inferiority Trial
|
N/A | |
Completed |
NCT03716869 -
Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
|
N/A | |
Recruiting |
NCT02824081 -
Neuroinflammation, Serotonin, Impulsivity and Suicide
|
N/A | |
Terminated |
NCT01099592 -
Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression
|
Phase 4 | |
Completed |
NCT03752853 -
Stress Systems and Psychotherapy in Depression
|
N/A | |
Recruiting |
NCT04480918 -
University of Iowa Interventional Psychiatry Service Patient Registry
|
||
Recruiting |
NCT04130958 -
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
|
N/A | |
Completed |
NCT03190772 -
The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation
|
N/A | |
Recruiting |
NCT04832750 -
Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
|
||
Terminated |
NCT02839798 -
NeoSync TMS Treatment for Bipolar I Depression
|
Phase 2 | |
Completed |
NCT00852592 -
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
|
Phase 3 |